NeoTX Therapeutics

NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.

NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies.

NeoTX Therapeutics was founded in 2015 by Asher Nathan. The company is headquartered in Rehovot, Israel.


NeoTX Therapeutics' STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful, yet safe, native antibacterial immune reaction.


NeoTX Therapeutics has raised $45M in a Series C round on Feb 19, 2020. This brings NeoTX's total funding to $60M to date.



  • Year founded: 2015
  • Funding Info: $60M over 3 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Rehovot
  • State: Rehovot
  • Country: Israel
Related businesses